StockNews.AI
ABBV
StockNews.AI
55 days

Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer

1. Elahere market valued at $502.56 million; projected to grow significantly. 2. AbbVie holds a 100% market share in elahere for ovarian cancer. 3. Hospital pharmacies dominate distribution, projected to see fast growth. 4. Ovarian neoplasms market expected to grow at CAGR of 29.67%. 5. Strategic collaborations and regulatory approvals recommended for future growth.

10m saved
Insight
Article

FAQ

Why Bullish?

AbbVie's complete market dominance and positive growth projections enhance its financial outlook. Similar past growth spikes for companies entering emerging cancer therapies suggest a bullish impact.

How important is it?

The elahere market's substantial growth prospects, combined with AbbVie's current dominance, positions it favorably for sustained revenue increases.

Why Long Term?

The elahere market is expected to expand substantially through 2034, benefiting AbbVie significantly. Historical context shows sustained success in oncology markets supports long-term growth.

Related Companies

IMGNVRTXREGN
Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "Elahere Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering.This report describes and explains the elahere market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.The global elahere market reached a value of nearly $502.56 million in 2024. The market is expected to grow from $502.56 million in 2024 to $1.72 billion in 2029 at a rate of 27.94%. The market is then expected to grow at a CAGR of 28.68% from 2029 and reach $6.07 billion in 2034. Growth in the historic period resulted from the rising healthcare expenditure, increase in demand for personalized medicine, rising awareness about early cancer detection and diagnosis and government initiatives for cancer screening programs. Factors that negatively affected growth in the historic period were low healthcare access in developing countries and lack of universal health coverage. Going forward, increasing healthcare access in emerging markets, increasing prevalence of ovarian cancer, increasing aging population, unmet need in ovarian cancer treatment and pipeline expansion will drive the growth. Factor that could hinder the growth of the elahere market in the future include high costs, limited target population, adverse side effects, diagnostic dependency, regulatory and reimbursement challenges and market competition.The global elahere market is highly concentrated, with only one player in the market. The top competitor in the market made up 100% of the total market in 2023. AbbVie Inc. (ImmunoGen) was the largest competitor with a 100% share of the market.North America was the largest region in the elahere market, accounting for 97.09% or $487.92 million of the total in 2024. It was followed by Western Europe, Eastern Europe and then the other regions. Going forward, the fastest-growing regions in the elahere market will be Western Europe and Eastern Europe where growth will be at CAGRs of 93.26% and 81.66% respectively.The elahere market is segmented by clinical indication into ovarian neoplasms, fallopian tube neoplasms and peritoneal neoplasms. The ovarian neoplasms market was the largest segment of the elahere market segmented by clinical indication, accounting for 85.44% or $429.38 million of the total in 2024. Going forward, the ovarian neoplasms segment is expected to be the fastest growing segment in the elahere market segmented by clinical indication, at a CAGR of 29.67% during 2024-2029.The elahere market is segmented by distribution channel into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies market was the largest segment of the elahere market segmented by distribution channel, accounting for 75.50% or $379.45 million of the total in 2024. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the elahere market segmented by distribution channel, at a CAGR of 33.81% during 2024-2029.The elahere market is segmented by end-users into hospitals, specialty centers and other end-users. The hospitals market was the largest segment of the elahere market segmented by end-users, accounting for 66.30% or $333.2 million of the total in 2024. Going forward, the hospitals segment is expected to be the fastest growing segment in the elahere market segmented by end-users, at a CAGR of 32.00% during 2024-2029.The top opportunities in the elahere market segmented by clinical indication will arise in the ovarian neoplasms segment, which will gain $1.14 billion of global annual sales by 2029. The top opportunities in the elahere market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $921.89 million of global annual sales by 2029. The top opportunities in the elahere market segmented by end-users will arise in the hospitals segment, which will gain $1.0 billion of global annual sales by 2029. The elahere market size will gain the most in the USA at $424.15 million.Market-trend-based strategies for the elahere market include European approval for elahere in platinum-resistant ovarian cancer, strategic collaboration targets for advanced ovarian cancer treatment and advanced diagnostic tool aims to enhance ovarian cancer treatment.Player-adopted strategies in the elahere market include focus on strengthening its business capabilities through strategic acquisitions.To take advantage of the opportunities, the analyst recommends the elahere companies to focus on expanding regulatory approvals for targeted therapies, focus on strategic collaborations for treatment development, focus on developing advanced diagnostic tools, focus on the ovarian neoplasms segment, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2B promotions, participate in trade shows and events, focus on the online pharmacies segment, focus on the hospitals segment and focus on targeting the aging population.Major Market Trends Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian CancerStrategic Collaboration Targets for Advanced Ovarian Cancer TreatmentAdvanced Diagnostic Tool Aims to Enhance Ovarian Cancer Treatment Markets Covered: Clinical Indication: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal NeoplasmsDistribution Channel: Hospital Pharmacies; Retail Pharmacies; Online PharmaciesEnd-User: Hospitals; Specialty Centers; Other End-Users Report AttributeDetailsNo. of Pages249Forecast Period2024 - 2034Estimated Market Value (USD) in 2024$502.6 MillionForecasted Market Value (USD) by 2034$6070 MillionCompound Annual Growth Rate28.3%Regions CoveredGlobal Key Topics Covered:Market Characteristics Elahere Market Definition and SegmentationsMarket Segmentation by Clinical Indication Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal Neoplasms Market Segmentation by Distribution Channel Hospital PharmaciesRetail PharmaciesOnline Pharmacies Market Segmentation by End-Users HospitalsSpecialty CentersOther End-Users Elahere Market Biologic Drug Characteristics Molecule TypeRoute of Administration (ROA)Mechanism of Action (MOA)Safety and Efficacy Global Elahere Growth Analysis and Strategic Analysis Framework Global Elahere PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors) Analysis of End Users for B2B Markets End Users HospitalsSpecialty CentersOther End Users Global Market Size and GrowthMarket SizeHistoric Market Growth, 2019-2024, Value ($ Million)Forecast Market Growth, 2024-2029, 2034F Value ($ Million)Global Elahere Total Addressable Market (TAM) Global Elahere Pricing Analysis & ForecastsGlobal Elahere Market Segmentation Global Elahere Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2029F, 2034F, Value ($ Million)Global Elahere Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2029F, 2034F, Value ($ Million)Global Elahere Market, Segmentation by End-Users, Historic and Forecast, 2019-2024, 2029F, 2034F, Value ($ Million) Global Elahere Epidemiology of Clinical Indications Incidence and Prevalence of Clinical Indications Elahere Market, Regional and Country Analysis Global Elahere Market, by Region, Historic and Forecast, 2019-2024, 2029F, 2034F, Value ($ Million)Global Elahere Market, by Country, Historic and Forecast, 2019-2024, 2029F, 2034F, Value ($ Million) Competitive Landscape and Company Profiles AbbVie Inc. (ImmunoGen) Global Elahere Market Pipeline AnalysisKey Mergers and Acquisitions AbbVie Acquired ImmunoGen Opportunities and Strategies Global Elahere Market in 2029 - Countries Offering Most New OpportunitiesGlobal Elahere Market in 2029 - Segments Offering Most New OpportunitiesGlobal Elahere Market in 2029 - Growth Strategies Market Trend Based StrategiesCompetitor Strategies About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Elahere Market Elahere Market Elahere Market

Related News